嵌合抗原受体
医学
汽车T细胞治疗
淋巴瘤
细胞疗法
CD19
肿瘤科
耐火材料(行星科学)
弥漫性大B细胞淋巴瘤
人口
临床试验
内科学
挽救疗法
免疫学
T细胞
细胞
化疗
抗原
免疫系统
生物
环境卫生
天体生物学
遗传学
作者
Hannah Kinoshita,Catherine M. Bollard,Keri Toner
标识
DOI:10.1053/j.seminhematol.2023.11.007
摘要
Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed or refractory diffuse large B cell lymphoma (DLBCL) with 3 CD19 targeting products now FDA-approved for this indication. However, up to 60% of patients ultimately progress or relapse following CAR-T cell therapy. Mechanisms of resistance to CAR-T cell therapy in patients with DLBCL are likely multifactorial and have yet to be fully elucidated. Determining patient, tumor and therapy-related factors that may predict an individual's response to CAR-T cell therapy requires ongoing analysis of data from clinical trials and real-world experience in this population. In this review we will discuss the factors identified to-date that may contribute to failure of CAR-T cell therapy in achieving durable remissions in patients with DLBCL.
科研通智能强力驱动
Strongly Powered by AbleSci AI